FLT3 and acute myeloid leukemia: In the recent phase II randomized RADIUS trial, maintenance therapy of midostaurin following allo-SCT did not appear to improve the prognosis of the SOC therapy with or without midostaurin after allo-SCT for AML patients with FLT3 mutations (Table 3) [69].